Last reviewed · How we verify
low dose GR1603 in phase Ⅱ
At a glance
| Generic name | low dose GR1603 in phase Ⅱ |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |